Skip to main content

Qiagen N.V. (QGEN)

NYSE: QGEN · IEX Real-Time Price · USD
54.20 -0.36 (-0.66%)
Dec 3, 2021 4:00 PM EST - Market closed

Company Description

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide.

The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables.

It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services.

It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation.

The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Qiagen N.V.
Qiagen Logo
CountryNetherlands
Founded1986
IPO DateJun 28, 1996
IndustryLife Sciences Tools & Services
SectorHealth Care
Employees6,000
CEOThierry Bernard

Contact Details

Address:
Hulsterweg 82
Venlo, Limburg 5912 PL
Netherlands
Phone31 77 355 6600
Websiteqiagen.com

Stock Details

Ticker SymbolQGEN
ExchangeNYSE
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001015820

Key Executives

NamePosition
Thierry BernardChief Executive Officer, MD and Member of Management Board
Dr. Roland SackersChief Financial Officer, MD and Member of Management Board
Dr. Barthold PieningSenior Vice President and Head of Global Operations
John GilardiVice President of Corporate Communications and Investor Relations
Stephany FosterSenior Vice President and Head of Human Resources
Dr. Thomas SchweinsSenior Vice President of Life Science Business Area
Dr. Thomas TheuringerSenior Director and Head of External Communications
Jean-Pascal ViolaSenior Vice President, Head of Molecular Diagnostics Business Area and Corporate Business Development
Dr. Jonathan G. Sheldon Ph.D.Senior Vice President of Qiagen Digital Insights Business Area
Thomas NeidertVice President of Global Treasury

Latest SEC Filings

DateTypeTitle
Nov 5, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 5, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jul 30, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jul 30, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jul 30, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jul 12, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 4, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 4, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 26, 2021SDSpecialized disclosure report
Mar 4, 2021IRANNOTICENotice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
View All SEC Filings